Intra-articular drug delivery systems for the treatment of rheumatic diseases: A review of the factors influencing their performance

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 73, Issue 2, 2009, Pages 205-218

  Butoescu, N ^a   Jordan, O ^a   Doelker, E ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Depot formulation; Drug delivery; Intra articular; Liposomes; Microparticles; Nanoparticles; Osteoarthritis; Review; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BETAMETHASONE SODIUM PHOSPHATE; CALCIUM ALGINATE; CELECOXIB; CHITOSAN; CORTICOSTEROID; DEXAMETHASONE; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FLURBIPROFEN; GELATIN; INFLIXIMAB; KETOPROFEN; LIPOSOME; METHOTREXATE; MICROSPHERE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NANOPARTICLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHOSPHOLIPID; POLYGLACTIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TACROLIMUS; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; VERTEPORFIN;

ANALGESIA; ARTHRITIS; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; ENCAPSULATION; HUMAN; NONHUMAN; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; INJECTIONS, INTRA-ARTICULAR; JOINTS; KINETICS; OSTEOARTHRITIS; PARTICLE SIZE; SOLUBILITY;

EID: 70349335682     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.06.009     Document Type: Review

References (166)

1. Studer R.K., Bergman R., Stubbs T., and Decker K. Chondrocyte response to growth factors is modulated by p38 mitogen-activated protein kinase inhibition. Arthritis Res. Ther. 6 (2004) R56-R64
2. Kang S., Jung M., Kim C.W., and Shin D.Y. Inactivation of p38 kinase delays the onset of senescence in rabbit articuilar chondrocytes. Mech. Ageing Dev. 126 (2005) 591-597
3. Haddad J.J. VX-745, Vertex pharmaceuticals. Curr. Opin. Invest. Drugs 2 (2001) 1070-1076
4. Kumar S., Votta B.J., Rieman D.J., Badger A.M., Gowen M., and Lee J.C. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J. Cell. Physiol. 187 (2001) 294-303
5. Pargellis C., and Regan J. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr. Opin. Invest. Drugs 4 (2003) 566-571
6. Studer R.K., and Chu C.R. p38 MAPK and COX2 inhibition modulate human chondrocyte response to TGF-β. J. Orthop. Res. 23 (2005) 454-461
7. Albert C., Brocq O., Gerard D., Roux C., and Euller-Ziegler L. Septic knee arthritis after intra-articular hyaluronate injection: two case reports. Joint Bone Spine 73 (2006) 205-207
8. Raynauld J.-P., Buckland-Wright C., Ward R., Choquette D., Haraoui B., Martel-Pelletier J., Uthman I., Khy V., Tremblay J., Bertrand C., and Martel-Pelletier J. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 48 (2003) 370-377
9. Gray R.G., and Gottlieb N.L. Intra-articular corticosteroids. Clin. Orthop. Rel. Res. 177 (1983) 235-263
10. Gaffney K., Ledingham J., and Perry J.D. Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response. Ann. Rheum. Dis. 54 (1995) 379-381
11. Gordon G.V., and Schumacher H.R. Electron microscopic study of depot corticosteroid crystals with clinical studies after intra-articular injection. J. Rheumatol. 61 (1978) 7-14
12. Ellman M.H., and Becker M.A. Crystal-induced arthropathies: recent investigative advances. Curr. Opin. Rheumatol. 18 (2006) 249-255
13. Tosu T. Steroid induced arthropathy. J. Joint Surg. 11 (1992) 87-95
14. Moore G.F. Arthrocentesis technique and intraarticular therapy. In: Koopman W.J., and Moreland L.W. (Eds). Arthritis and Allied Conditions - A Textbook of Rheumatology (2005), Lippincott Williams & Wilkins, Philadelphia 775-785
15. Larsen C., Øsergaard J., Larsen S.W., Jensen H., Jacobsen S., Lindegaard C., and Andersen A.H. Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J. Pharm. Sci. 97 (2008) 4622-4654
16. Tarner I.H., and Muller-Ladner U. Drug delivery systems for the treatment of rheumatoid arthritis. Exp. Opin. Drug Deliv. 5 (2008) 1027-1037
17. Traister R.S., and Hirsch R. Gene therapy for arthritis. Mod. Rheumatol. 18 (2008) 2-14
18. Hugle T., and van Laar J.M. Stem cell transplantation for rheumatic autoimmune diseases. Arthritis Res. Ther. 10 (2008)
19. Strand V., Kimberly R., and Isaacs J.D. Biologic therapies in rheumatology: lessons, learned future directions. Nat. Rev. Drug Discov. 6 (2007) 75-92
20. Revell P.A., Mayston V., and Lalor P. The synovial membrane in osteoarthritis: a histological study including the characterization of the cellular infiltrate present in inflammatory osteoarthritis using monoclonal antibodies. Ann. Rheum. Dis. 47 (1988) 300-307
21. Woo S.L.Y., An K.N., and Arnoczky S.P. Anatomy, biology, and biomechanics of tendon ligament and meniscus. In: Simon S.R. (Ed). Orthopaedic Basic Science (1994), American Academy of Orthopaedic Surgeons, Chicago 45-88
22. Ghadially F.N. Fine structure of joints. In: Sokoloff L. (Ed). The Joints and Synovial Fluid (1978), Academic, San Diego 105-168
23. Mankin H.J., and Mow V.C. Form and function of articular cartilage. In: Simon S.R. (Ed). Orthopaedic Basic Science (1994), American Academy of Orthopaedic Surgeons, Chicago 2-44
24. Gardner D.L., and McGillivray D.C. Living cartilage is not smooth. Ann. Rheum. Dis. 30 (1971) 3-9
25. Jurvelin J.S., Müller D.J., Wong M., and Suder D. Surface and subsurface morphology of bovine humeral articular cartilage by atomic force transmission electron microscopy. J. Struct. Biol. 117 (1996) 45-54
26. V.K. Shekhawat, M.P. Laurent, C. Muehlman, M.A. Wimmer, Surface topography of viable articular cartilage measured with scanning white light interferometry, Osteoarthr. Cartil., 2009, in press.
27. Price F.M., Levick J.R., and Mason R.M. Glycosaminoglycan concentration in synovium and other tissues of rabbit knee in relation to synovial hydraulic resistance. J. Physiol. 495 (1996) 803-820
28. Davies D.V. Observations on the volume, viscosity and nitrogen content of synovial fluid with a note on the histological appearance of synovial membrane. J. Anat. 78 (2003) 68-78
29. Poole A.R., and Howell D.S. Etiopathogenesis of osteoarthritis. In: Moskowitz R.W., Howell D.S., Altman R.D., Buckwalter J.A., and Goldberg V.M. (Eds). Osteoarthritis (2001), Diagnosis and Medical/Surgical Management, W.B. Saunders Company, Philadelphia 29-47
30. Sweeney S.E., and Firestein G.S. Rheumatoid arthritis: regulation of synovial inflammation. Int. J. Biochem. Cell Biol. 36 (2004) 372-378
31. Springfield D.S., Bolander M.E., Friedlaender G.E., and Lane N. Molecular and cellular biology of inflammation and neoplasia. In: Simon S.R. (Ed). Orthopaedic Basic Science (1994), American academy of orthopaedic surgeons, Rosemont 219-276
32. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 14 (1996) 397-440
33. Magne D., Palmer G., Barton J., Mθzin F., Talabot-Ayer D., Bas S., Duffy T., Noger M., Guerne P.A., Nicklin M., and Gabay C. The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res. Ther. 8 (2006) R80
34. Choy E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl. J. Med. 344 (2001) 907-916
35. Chabaud M., Garnero P., Dayer J.M., Guerne P.A., Fossiez F., and Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 12 (2000) 1092-1099
36. Das S.K., and Farooqi A. Osteoarthritis. Best Pract. Res. Clin. Rheumatol. 22 (2008) 657-675
37. Sharma L., Kapoor D., and Issa S. Epidemiology of osteoarthritis: an update. Curr. Opin. Rheumatol. 18 (2006) 147-156
38. Lawrence R.C., Helmick C.G., Arnett F.C., Deyo R.A., Felson D.T., Giannini E.H., Heyse S.P., Hirsch R., Hochberg M.C., Hunder G.G., Liang M.H., Pillemer S.R., Steen V.D., and Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41 (1998) 778-799
39. Hochberg M.C., Altman R.D., and Brandt K.D. Guidelines for the medical management of osteoarthritis. Arthritis Rheum. 38 (1995) 1535-1540
40. Brandt K.D. A critique of the 2000 update of the American College of Rheumatology recommendations for management of hip and knee osteoarthritis. Arthritis Rheum. 44 (2001) 2451-2455
41. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W.J., Dieppe P., Gunther K., Hauselmann H., Herrero-Beaumont G., Kaklamanis P., Lohmander S., Leeb B., Lequesne M., Mazieres B., Martin-Mola E., Pavelka K., Pendleton A., Punzi L., Serni U., Swoboda B., Verbruggen G., Zimmerman-Gorska I., and Dougados M. EULAR recommendations 2003: an evidence-based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann. Rheum. Dis. 62 (2003) 1145-1155
42. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., Bierma-Zeinstra S., Brandt K.D., Croft P., Doherty M., Dougados M., Hochberg M., Hunter D.J., Kwoh K., Lohmander L.S., and Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr. Cartil. 16 (2008) 137-162
43. Felson D.T. Osteoarthritis of the knee. New Engl. J. Med. 354 (2006) 841-848
44. Michael L.T., and Kelley T. Nonsurgical management of osteoarthritis of the knee. JAAPA 19 (2006) 26-32
45. Hogenmiller M.S., and Lozada C.J. An update on osteoarthritis therapeutics. Curr. Opin. Rheumatol. 18 (2006) 256-260
46. Uthman I., Raynauld J.-P., and Haraoui B. Intra-articular therapy in osteoarthritis. Postgrad. Med. J. 79 (2003) 449-453
47. Lozada C.J., and Altman R.D. Management of osteoarthritis. In: Koopman W.J., and Moreland L.W. (Eds). Arthritis and Allied Conditions - A Textbook of Rheumatology (2005), Lippincott Williams & Wilkins, Philadelphia 2257-2276
48. Simon L.S., and Stand V. The pharmacological treatment of osteoarthritis. In: Moskowitz R.W., Howell D.S., Altman R.D., Buckwalter J.A., and Goldberg V.M. (Eds). Osteoarthritis (2001), W.B. Saunders Company, Philadelphia 371-391
49. Zhang W., Jones A., and Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? - a meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 63 (2004) 901-907
50. Schnitzer T., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., Gitton X., Krammer G., Mellein B., Matchaba P., GImona A., and Hawley C. Comparison of luminacoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 363 (2004) 665-674
51. Leopold S.S., Redd B.B., Warme W.J., Wehrle P.A., Pettis P.D., and Shott S. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. A prospective, randomized trial. J. Bone Joint Surg. Am. 85-A (2003) 1197-1203
52. Vlad S.C., LaValley M.P., McAlindon T.E., and Felson D.T. Glucosamine for pain in osteoarthritis: why do trial results differ?. Arthritis Rheum. 56 (2007) 2267-2277
53. McAlindon T.E., and Biggee B.A. Nutritional factors and osteoarthritis: recent developments. Curr. Opin. Rheumatol. 17 (2005) 647-652
54. El Desoky E.S. Pharmacotherapy of rheumatoid arthritis: an overview. Curr. Ther. Res. 62 (2001) 92-112
55. Li E.K., Tam L.-S., and Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin. Ther. 26 (2004) 447-459
56. Kitahara K., and Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr. Opin. Rheumatol. 19 (2007) 238-245
57. Kawai S., and Yamamoto K. Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology (Oxford) 45 (2006) 441-444
58. Furst D.E., Saag K., Fleischmann M.R., Sherrer Y., Block J.A., Schnitzer T., Rutstein J., Baldassare A., Kaine J., Calabrese L., Dietz F., Sack M., Senter R.G., Wiesenhutter C., Schiff M., Stein C.M., Satoi Y., Matsumoto A., Caldwell J., Harris R.E., Moreland L.W., Hurd E., Yocum D., and Stamler D.A. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. 46 (2002) 2020-2028
59. Scott D.L., and Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. Reply, New Engl. J. Med. 355 (2006) 2048
60. Sibilia J., Gottenberg J.E., and Mariette X. Rituximab: a new therapeutic alternative in rheumatoid arthritis. Joint Bone Spine 75 (2008) 526-532
61. Esenyel C., Demirhan M., Esenyel M., Sonmez M., Kahraman S., Senel B., and Ozdes T. Comparison of four different intra-articular injection sites in the knee: a cadaver study. Knee Surg. Sports Traumatol. Arthrosc. 15 (2007) 573-577
62. Dabke V H. Accuracy of needle placement into the intra-articular space of the knee. J. Bone Joint Surg. Am. 86-A (2004) 433-434
63. Post III J.H. Accuracy of needle placement into the intra-articular space of the knee. J. Bone Joint Surg. Am. 85-A (2003) 2481
64. Jackson D.W., Evans N.A., and Thomas B.M. Accuracy of needle placement into the intra-articular space of the knee. J. Bone Joint Surg. Am. 84-A (2002) 1522-1527
65. Neustadt D.H. Intra-articular therapy. In: Moskowitz R.W., Howell D.S., Altman R.D., Buckwalter J.A., and Goldberg V.M. (Eds). Osteoarthritis (2001), W.B. Saunders Company, Philadelphia 393-411
66. Ayral X. Injections in the treatment of osteoarthritis. Best Pract. Res. Clin. Rheumatol. 15 (2001) 609-626
67. Wooley P.H., Grimm M.J., and Radin E.L. The structure and function of joints. In: Koopman W.J., and Moreland L.W. (Eds). Arthritis and Allied Conditions - A Textbook of Rheumatology (2005), Lippincott Williams & Wilkins, Philadelphia 149-175
68. Graabæk P.M. Ultrastructural evidence for two distinct types of synoviocytes in rat synovial membrane. J. Ultrastruct. Res. 78 (1982) 321-339
69. Momberger T.S., Levick J.R., and Mason R.M. Hyaluronan secretion by synoviocytes is mechanosensitive. Matrix Biol. 24 (2005) 510-519
70. Müller-Ladner U., Gay R.E., and Gay S. Structure and functions of synoviocytes. In: Koopman W.J., and Moreland L.W. (Eds). Arthritis and Allied Conditions - A Textbook of Rheumatology (2005), Lippincott Williams & Wilkins, Philadelphia 271-287
71. Wilkinson L.S., Pitsillides A.A., Worrall J.G., and Edwards J.C.W. Light microscopic characterization of the fibroblast-like synovial intimal cell (synoviocyte). Arthritis Rheum. 35 (1992) 1179-1184
72. Senda H., Sakuma E., Wada I., Wang H.J., Maruyama H., and Matsui N. Ultrastructural study of cells at the synovium-cartilage junction: response of synovial cells of the rat knee joint to intra-articularly injected latex particles. Acta Anat. Nippon. 74 (1999) 525-535
73. Levick J.R. Permeability of the rheumatoid and normal synovium to specific plasma proteins. Arthritis Rheum. 24 (1981) 1550-1560
74. Simkin P.A. Synovial physiology. In: Koopman W.J., and Moreland L.W. (Eds). Arthritis and Allied Conditions - A Textbook of Rheumatology (2005), Lippincott, Williams & Wilkins, Philadelphia
75. Schurman D.J., and Kajiyama G. Antibiotic absorption from infected and normal joints using a rabbit knee joint model. J. Orthop. Res. 3 (1985) 185-188
76. Coleman P.J., Scott D., Ray J., Mason R.M., and Levick J.R. Hyaluronan secretion into the synovial cavity of rabbit knees and comparison with albumin turnover. J. Physiol. 503 (1997) 645-656
77. Betre H., Liu W., Zalutsky M.R., Chilkoti A., Kraus V.B., and Setton L.A. A thermally responsive biopolymer for intra-articular drug delivery. J. Control Rel. 115 (2006) 175-182
78. Song J., Suh C.H., Park Y.B., Lee S.H., Yoo N.C., Lee J.D., Kim K.H., and Lee S.K. A phase I/IIa study on intra-articular injection of holmium-166-chitosan complex for the treatment of knee synovitis of rheumatoid arthritis. Eur. J. Nucl. Med. 28 (2001) 489-497
79. Shaw I.H., Knight C.G., and Dingle J.T. Liposomal retention of a modified anti-inflammatory steroid. Biochem. J. 158 (1976) 473-476
80. Bonanomi M.H., Velvart M., Stimpel M., Roos K.M., Fehr K., and Weder H.G. Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis. Rheumatol. Int. 7 (1987) 203-212
81. Williams A.S., Camilleri J.P., Goodfellow R.M., and Williams B.D. A single intra-articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigen-induced arthritis. Br. J. Rheumatol. 35 (1996) 719-724
82. Hou S.-M., and Yu H.-Y. Comparison of systemic absorption of aqueous and liposomal lidocaine following intra-articular injection in rabbits. J. Formos. Med. Assoc. 96 (1997) 141-142
83. ® by articular tissues following systemic and intra-articular administration. Biopharm. Drug Dispos. 19 (1998) 395-400
84. Edwards S.H.R., Cake M.A., Spoelstra G., and Read R.A. Biodistribution and clearance of intra-articular liposomes in a large animal model using a radiographic marker. J. Liposome Res. 17 (2007) 249-261
85. Lu Y., Zhang G., Sun D., and Zhong Y. Preparation and evaluation of biodegradable flurbiprofen gelatin micro-spheres for intra-articular administration. J. Microencapsul. 24 (2007) 515-524
86. Thakkar H., Sharma R.K., Mishra A.K., Chuttani K., and Murthy R.S.R. Efficacy of chitosan microspheres for controlled intra-articular delivery of celecoxib in inflamed joints. J. Pharm. Pharmacol. 56 (2004) 1091-1099
87. Liang L., Jackson J., Min W., Risovic V., Wasan K.M., and Burt H.M. Methotrexate loaded poly(l-lactic acid) microspheres for intra-articular delivery of methotrexate to the joint. J. Pharm. Sci. 93 (2003) 943-956
88. Liang L.S., Wong W., and Burt H.M. Pharmacokinetic study of methotrexate following intra-articular injection of methotrexate loaded poly(L-lactic acid) microspheres in rabbits. J. Pharm. Sci. 94 (2005) 1204-1215
89. Rothenfluh D.A., Bermudez H., O'Neil C.P., and Hubbell J.A. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat. Mater. 7 (2008) 248-254
90. Koning G.A., Schiffelers R.M., Wauben M.H., Kok R.J., Mastrobattista E., Molema G., ten Hagen T.L.M., and Storm G. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum. 54 (2006) 1198-1208
91. Garrood T., and Pitzalis C. Targeting the inflamed synovium: the quest for selectivity. Arthritis Rheum. 54 (2006) 1055-1060
92. R. Margalit, D. Peer, Lipidated glycoprotein particles and methods of use, Patent No. WO/2006/017195, 2006.
93. Tanaka H., Sugita T., Yasunaga Y., Shimose S., Deie M., Kubo T., Murakami T., and Ochi M. Efficiency of magnetic liposomal transforming growth factor-beta 1 in the repair of articular cartilage defects in a rabbit model. J. Biomed. Mater. Res. A 73A (2005) 255-263
94. Butoescu N., Jordan O., Burdet P., Hebert C., Stadelmann P., Petri-Fink A., Hofmann H., and Doelker E. Dexamethasone-containing biodegradable superparamagnetic microparticles for intra-articular administration: physicochemical and magnetic properties, and in vitro and in vivo drug release. Eur. J. Pharm. Biopharm. 72 (2009) 529-538
95. Butoescu N., Jordan O., Petri-Fink A., Hofmann H., and Doelker E. Co-encapsulation of dexamethasone 21-acetate and SPIONs into biodegradable polymeric microparticles designed for intra-articular delivery. J. Micoencapsul. 25 (2008) 339-350
96. Butoescu N., Seemayer C.A., Palmer G., Guerne P.-A., Gabay C., Doelker E., and Jordan O. Magnetically retainable microparticles for drug delivery to the joint: efficacy studies on an antigen-induced arthritis model in mice. Arthritis Res. Ther. 11 (2009) R72
97. Schulze K., Koch A., Schopf B., Petri A., Steitz B., Chastellain M., Hofmann M., Hofmann H., and von Rechenberg B. Intraarticular application of superparamagnetic nanoparticles and their uptake by synovial membrane - an experimental study in sheep. J. Magn. Magn. Mater. 293 (2005) 419-432
98. Hellstern D., Schultze K., Schopf B., Petri-Fink A., Steitz B., Kamau S., Hilbe M., Koch-Schneidemann S., Vaughan L., Hottiger M., Hofmann H., Hofmann M., and von Rechenberg B. Systemic distribution and elimination of plain and with Cy3.5 functionalized poly(vinyl alcohol) coated superparamagnetic maghemite nanoparticles after intraarticular injection in sheep in vivo. J. Nanosci. Nanotechnol. 6 (2006) 3261-3268
99. Shaw I.H., and Dingle J.T. Liposomes as steroid carriers in the intra-articular therapy of rheumatoid arthritis. In: Gregoriadis G., and Allison A.C. (Eds). Liposomes in Biological Systems (1980), John Wiley & Sons, Ltd., London pp. 299-324
100. Bonanomi M.H., Velvart M., and Weder H.G. Fate of different kinds of liposomes containing dexamethasone palmitate after intra-articular injection into rabbit joints. J. Microencapsul. 4 (1987) 189-200
101. Türker S., Erdogan S., Özer A.Y., Ergün E.L., Tuncel M., Bilgili H., and Deveci S. Scintigraphic imaging of radiolabelled drug delivery systems in rabbits with arthritis. Int. J. Pharm. 296 (2005) 34-43
102. De Silva M., Hazleman B.L., Page Thomas D.P., and Wraight P. Liposomes in arthritis: a new approach. Lancet 313 (1979) 1320-1322
103. Barrera P., Blom A., van Lent P.L., van Bloois L., Beijnen J.H., Van Rooijen N., Waal Malefijt M.C., van de Putte L.B., Storm G., and van den Berg W.B. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. 43 (2000) 1951-1959
104. Howie D.W., Manthey B., Hay S., and Vernon-Roberts B. The synovial response to intraarticular injection in rats of polyethylene wear particles. Clin. Orthop. Relat. Res. 292 (1993) 352-357
105. Horisawa E., Kubota K., Tuboi I., Sato K., Yamamoto H., Takeuchi H., and Kawashima Y. Size-dependency of DL-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm. Res. 19 (2002) 132-139
106. Nishide M., Kamei S., Takakura Y., and Tamai S. Fate of biodegradable d,l-lactic acid oligomer microspheres in the articulus. J. Bioact. Compat. Polym. 14 (1999) 385-398
107. Ratcliffe J.H., Hunneyball I.M., Smith A., Wilson C.G., and Davis S.S. Preparation and evaluation of biodegradable polymeric systems for the intra-articular delivery of drugs. J. Pharm. Pharmacol. 36 (1984) 431-436
108. Ratcliffe J.H., Hunneyball I.M., Wilson C.G., Smith A., and Davis S.S. Albumin microspheres for intra-articular drug-delivery: investigation of their retention in normal and arthritic knee joints of rabbits. J. Pharm. Pharmacol. 39 (1986) 290-295
109. Ramesh D.V., Tabata Y., and Ikada Y. Bioabsorbable microspheres for local drug release in the articulus. J. Bioact. Compat. Polym. 14 (1999) 137-149
110. Liggins R.T., Cruz T., Min W., Liang L., Hunter W.L., and Burt H.M. Intra-articular treatment of arthritis with microsphere formulations of paclitaxel: biocompatibility and efficacy determinations in rabbits. Inflamm. Res. 53 (2004) 363-372
111. Sarma A.V., Powell G.L., and LaBerge M. Phospholipid composition of articular cartilage boundary lubricant. J. Orthop. Res. 19 (2001) 671-676
112. Kirby C., Clarke J., and Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J. 186 (1980) 591-598
113. Schwendener R.A., Lagocki P.A., and Rahman Y.E. The effects of charge and size on the interaction of unilamellar liposomes with macrophages. Biochim. Biophys. Acta, Biomembr. 772 (1984) 93-101
114. Phillips N.C., Page Thomas D.P., Knight C.G., and Dingle J.T. Liposome-incorporated corticosteroids. II. Therapeutic activity in experimental arthritis. Ann. Rheum. Dis. 38 (1979) 553-557
115. Setton L. Polymer therapeutics: reservoir drugs. Nat. Mater. 7 (2008) 172-174
116. Bozdag S., Calis S., Kas H.S., Ercan M.T., Peksoy I., and Hincal A.A. In vitro evaluation and intra-articular administration of biodegradable microspheres containing naproxen sodium. J. Microencapsul. 18 (2000) 443-456
117. Cai L., Okumu F.W., Cleland J.L., Beresini M., Hogue D., Lin Z., and Filvaroff E.H. A slow release formulation of insulin as a treatment for osteoarthritis. Osteoarthr. Cartil. 10 (2002) 692-706
118. Tuncay M., Calis S., Kas H.S., Ercan M.T., Peksoy I., and Hincal A.A. Diclofenac sodium incorporated PLGA (50:50) microspheres: formulation considerations and in vitro/in vivo evaluation. Int. J. Pharm. 195 (2000) 179-188
119. Mierisch C.M., Cohen S.B., Jordan L.C., Robertson P.G., Balian G., Diduch D.R., and Robertson P.G. Transforming growth factor-β in calcium alginate beads for the treatment of articular cartilage defects in the rabbit. Arthroscopy 18 (2002) 892-900
120. Brown K.E., Leong K., Huang C., Dalal R., Green G.D., Haimes H.B., Jimenez P.A., and Bathon J. Gelatin/chondroitin 6-sulphate microspheres for the delivery of therapeutic proteins to the joint. Arthritis Rheum. 41 (1998) 2185-2195
121. Horisawa E., Hirota T., Kawazoe S., Yamada J., Yamamoto H., Takeuchi H., and Kawashima Y. Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for intra-articular delivery system in antigen-induced arthritic rabbit. Pharm. Res. 19 (2002) 403-410
122. Liang L.S., Jackson J., Min W., Risovic V., Wasan K.M., and Burt H.M. Methotrexate loaded poly(L-lactic acid) microspheres for intra-articular delivery of methotrexate to the joint. J. Pharm. Sci. 93 (2004) 943-956
123. Cavalier M., Benoit J.P., and Thies C. The formation and characterization of hydrocortisone-loaded poly((±)-lactide) microspheres. J. Pharm. Pharmacol. 38 (1986) 249-253
124. Bozdag S., Calis S., Kas H.S., Ercan M.T., Peksoy I., and Hincal A.A. In vitro evaluation and intra-articular administration of biodegradable microspheres containing naproxen sodium. J. Micoencapsul. 18 (2001) 443-456
125. Thakkar H., Sharma R.K., Mishra A.K., Chuttani K., and Murthy R.S.R. Efficacy of chitosan microspheres for controlled intra-articular delivery of celecoxib in inflamed joints. JPP 56 (2004) 1091-1099
126. Taylor A.R., Harbison J.S., and Pepler C. Synovectomy of the knee in rheumatoid arthritis. II. Results of surgery. Ann. Rheum. Dis. 31 (1972) 159-161
127. Page Thomas D.P., and Phillips N.C. Intra-articular liposomal therapy. In: Dingle J.T., Jacques P.J., and Shaw I.H. (Eds). Lysosomes in Applied Biology and Therapeutics (1979), North-Holland, Publishing Company, Amsterdam 601-623
128. Noble J., Jones A.G., Davies M.A., Sledge C.B., Kramer R.I., and Livni E. Leakage of radioactive particle systems from a synovial joint studied with a gamma camera. Its application to radioactive synovectomy. J. Bone Joint Surg. 65-A (1983) 381-389
129. Mumper R.J., Mills B.J., Ryo U.Y., and Jay M. Polymeric microspheres for radionuclide synovectomy containing neutron-activated holmium-166. J. Nucl. Med. 33 (1992) 398-402
130. Highton J., Guevremont D., Thomson J., Carlisle B., and Tucker I. A trial of clodronate liposomes as anti-macrophage treatment in a sheep model of arthritis. Clin. Exp. Rheumatol. 17 (1999) 43-48
131. van Lent P.L.E.M., Holthuysen A.E.M., Van Rooijen N., Van De Putte L.B.A., and van den Berg W. Local removal of phagocytic synovial lining cells by clodronate-liposomes decreases cartilage destruction during collagen type II arthritis. Ann. Rheum. Dis. 57 (1998) 408-413
132. Knight C.G., and Shaw I.H. Liposomes as carriers of anti-inflammatory steroids. In: Dingle J.T., Jacques P.J., and Shaw I.H. (Eds). Lysosomes in Applied Biology and Therapeutics (1979), North-Holland Publishing Company, Amsterdam 575-601
133. Dingle J.T., Gordon J.L., Hazleman B.L., Knight C.G., Page Thomas D.P., Phillips N.C., Shaw I.H., Fildes F.J.T., Oliver J.E., Jones G., Turner E.H., and Lowe J.S. Novel treatment for joint inflammation. Nature 271 (1977) 372-373
134. Bard D.R., Knight C.G., and Page Thomas D.P. The retention and distribution in the rabbit knee of a radionuclide complexed with a lipophilic chelator in liposomes. Clin. Exp. Rheumatol. 1 (1983) 113-117
135. Trif M., Guillen C., Vaughan D.M., Telfer J.M., Brewer J.M., Roseanu A., and Brock J.H. Liposomes as possible carriers for lactoferrin in the local treatment of inflammatory diseases. Exp. Biol. Med. 226 (2001) 559-564
136. 3H]methotrexate injected into normal or arthritic rabbit joints. J. Pharm. Pharmacol. 40 (1987) 464-468
137. Foong W.C., and Green K.L. Treatment of antigen-induced arthritis in rabbits with liposome-entrapped methotrexate injected intra-articularly. J. Pharm. Pharmacol. 45 (1993) 204-209
138. Abe T., Yamada H., Nakajima H., Kikuchi T., Takaishi H., Tadakuma T., Fujikawa K., and Toyama Y. Repair of full-thickness cartilage defects using liposomal transforming growth factor-beta 1. J. Orthop. Sci. 8 (2003) 92-101
139. Hunziker E.B. Growth-factor-induced healing of partial-thickness defects in adult articular cartilage. Osteoarthr. Cartil. 9 (2001) 22-32
140. Lopez-Garcia F., Vasquez-Auton J.M., Gil F., Latoore R., Moreno F., Villalain J., and Gomez-Fernandez J.C. Intra-articular therapy of experimental arthritis with a derivative of triamcinolone acetonide incorporated in liposomes. J. Pharm. Pharmacol. 45 (1993) 576-578
141. Schultze K., Koch A., Petri-Fink A., Kamau S., Hottiger M., Hilbe M., Vaughan L., Hofmann M., Hofmann H., and von Rechenberg B. Uptake and biocompatibility of functionalized poly(vinylalcohol) coated superparamagnetic maghemite nanoparticles by synoviocytes in vitro. J. Nanosci. Nanotechnol. 6 (2006) 2829-2840
142. Thakkar H., Sharma R.K., Mishra A.K., Chuttani K., and Murthy R.S.R. Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS Pharm. Sci. Tech. 6 (2005) E65-E73
143. Inoue A., Takahashi K.A., Arai Y., Tonomura H., and Sakao K. The therapeutic effects of basic fibroblast growth factor contained in gelatin hydrogel microspheres on experimental osteoarthritis in the rabbit knee. Arthritis Rheum. 54 (2006) 264-270
144. Haerdi-Landerer M.C., Suter M.M., Steiner A., Wittenbrink M.M., Pickl A., and Gander B.A. In vitro cell compatibility and antibacterial activity of microencapsulated doxycycline designed for improved localized therapy of septic arthritis. J. Antimicrob. Chemother. 61 (2008) 332-340
145. Bragdon B., Bertone A.L., Hardy J., Simmons E.J., and Weisbrode S.E. Use of an isolated joint model to detect early changes induced by intra-articular injection of paclitaxel-impregnated polymeric microspheres. J. Invest. Surg. 14 (2001) 169-182
146. Burgess D.J., and Davis S.S. Potential use of albumin microspheres as a drug delivery system: II. In vivo deposition and release of steroids. Int. J. Pharm. 46 (1988) 69-76
147. Chinol M., Vallabhajosula S., Zuckerman J.D., and Goldsmith S.J. In-vivo stability of ferric hydroxide macroaggregates (FHMA). Is it a suitable carrier for radionuclides used in synovectomy?. Nucl. Med. Biol. 17 (1990) 479-486
148. Kothari K., Suresh S., Sarma H.D., Meera V., and Pillai M.R.A. 188Re-labeled hydroxyapatite particles for radiation synovectomy. Appl. Radiat. Isot. 58 (2003) 463-468
149. Hnatowich D.J., Kramer R.I., Sledge C.B., Noble J., and Shortkroff S. Dysprosium-165-ferric hydroxide macroaggregates for radiation synovectomy. J. Nucl. Med. 19 (1978) 303-308
150. Davies M.A., and Chinol M. Radiopharmaceuticals for radiation synovectomy. J. Nucl. Med. 30 (1989) 1047-1055
151. Lee S.H., Suh J.S., Kim H.S., Lee J.D., Song J., and Lee S.K. MR evaluation of radiation synovectomy of the knee by means of intra-articular injection of holmium-166-chitosan complex in patients with rheumatoid arthritis: results at 4-month follow-up. Korean J. Radiol. 4 (2003) 170-178
152. Cevc G., Schatzlein A., and Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim. Biophys. Acta, Biomembr. 1564 (2002) 21-30
153. Rother M., Lavins B.J., Kneer W., Lehnhardt K., Seidel E.J., and Mazgareanu S. Efficacy and safety of epicutaneous ketoprofen in Transferosome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomized controlled trial. Ann. Rheum. Dis. 66 (2007) 1178-1183
154. Gabay C. Cytokines and cytokine receptors. In: Koopman W.J., and Moreland L.W. (Eds). Arthritis and Allied Conditions - A Textbook of Rheumatology (2005), Lippincott Williams & Wilkins, Philadelphia 423-476
155. Schindler J.F., Monahan J.B., and Smith W.G. p38 pathway kinases as anti-inflammatory drug targets. J. Dent. Res. 86 (2007) 800-811
156. Mayer R.J., and Callahan J.F. p38 MAP kinase inhibitors: a future therapy for inflammatory diseases. Drug Discov. Today 3 (2006) 49-54
157. Badger A.M., Cook M.N., Lark M.W., Newman-Tarr T.M., Swift B.A., Nelson A.H., Barone F.C., and Kumar S. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J. Immunol. 161 (1998) 467-473
158. Badger A.M., Griswold D.E., Kapadia R., Blake S., Swift B.A., Hoffman S.J., Stroup G.B., Webb E., Rieman D.J., Gowen M., Boehm J.C., Adams J.L., and Lee J.C. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. 43 (2000) 175-183
159. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., and Griswold D.E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279 (1996) 1453-1461
160. Palladino M.A., Bahjat F.R., Theodorakis E.A., and Moldawer L.L. Anti-TNF-α therapies: the next generation. Nat. Rev. Drug Discov. 2 (2003) 736-746
161. Bagley M.C., Davis T., Dix M.C., Rokicki M.J., and Kipling D. Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells. Bioorg. Med. Chem. Lett. 17 (2007) 5107-5110
162. Ding C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr. Opin. Invest. Drugs 7 (2006) 1020-1025
163. Badger A.M., Blake S., Kapadia R., Sarkar S., Levin J., Swift B.A., Hoffman S.J., Stroup G.B., Miller W.H., Gowen M., and Lark M.W. Disease-modifying activity of SB 273005, an orally active, nonpeptide αvβ3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum. 44 (2001) 128-137
164. Braddock M., and Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev. Drug Discov. 3 (2004) 1-10
165. Rudolphi K., Gerwin N., Verzijl N., van der Kraan P., and van den Berg W. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthr. Cartil. 11 (2003) 738-746
166. Loher F., Bauer C., Landauer N., Schmall K., Siegmund B., Lehr H.A., Dauer M., Schoenharting M., Endres S., and Eigler A. The interleukin-1-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1T-cell activation. J. Pharmacol. Exp. Ther. 308 (2004) 583-590